Febuxostat for treating chronic gout.

Area of Science:

• Rheumatology and Immunology
• Pharmacology and Therapeutics

Background:

• Gout, a prevalent inflammatory arthritis, necessitates lowering serum uric acid (SUA) levels for effective chronic management.
• Febuxostat has demonstrated efficacy in reducing SUA levels below 6.0 mg/dL in clinical trials.

Purpose of the Study:

• To conduct a meta-analysis evaluating the benefits and harms of febuxostat for chronic gout management.
• To compare febuxostat's efficacy and safety against placebo and allopurinol.

Main Methods:

• Systematic literature search of multiple databases (Cochrane Library, MEDLINE, EMBASE) and clinical trial registries up to July 2011.
• Inclusion of controlled clinical trials and open-label trials (OLTs) of febuxostat at any dosage.
• Meta-analysis of extracted data, assessing risk of bias and summarizing continuous and dichotomous outcomes.

Main Results:

• Febuxostat significantly reduced SUA levels < 6.0 mg/dL compared to placebo and allopurinol across various doses.
• Higher febuxostat doses (120 mg, 240 mg) were associated with increased gout flares versus placebo in early treatment.
• Long-term follow-up showed no significant difference in gout flares between febuxostat (80-120 mg) and allopurinol.

Conclusions:

• Febuxostat is effective in achieving target SUA levels for gout patients.
• While initial gout flares may increase with febuxostat, long-term use shows comparable flare rates to allopurinol.
• Further research is indicated due to the variable quality of evidence.